Extended Data Fig. 6: Recovery of normal hematopoiesis in mice treated with AZD5582-based combination treatments.

a, Human CD45-labeled and HE-stained femoral sections and b, PB flow cytometry of Patient 9, 1, 22, 2 and 51 PDX mice during 4-week course of AZD5582 and AZD5582-based combination treatments. In (a), white broken lines in HE-stained images outline blood vessels containing erythrocytes and arrows indicate murine megakaryocytes. Femoral section and PB flow cytometry from a non-recipient NSG mice are shown as comparison. c, Following in vivo treatment with AZD5582 combined with venetoclax and AZD5582 combined with barasertib, Mac1⁺ Gr1^- monocytes and Mac1⁺ Gr1⁺ granulocytes were found in the recipient BM (representative flow cytometry plots shown). Mac1⁺ Gr1^- monocytes and Mac1⁺ Gr1⁺ granulocytes were identified by May-Grunwald Giemsa staining after treatment with AZD5582 and venetoclax.